PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY